首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MDC |
| Uniprot No | O00626 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-93aa |
| 氨基酸序列 | GPYGANMEDSVCCRDYVRYRLPLRVVKHFYWTSDSCPRPGVVLLTFRDKE ICADPRVPWVKMILNKLSQ |
| 预测分子量 | 8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MDC(CCL22)重组蛋白的参考文献示例(注：以下内容为模拟示例，仅供参考，实际文献需通过学术数据库查询)：
---
1. **标题**: *"High-yield expression and functional characterization of recombinant human MDC/CCL22 in Escherichia coli"*
**作者**: Smith A, et al.
**摘要**: 研究报道了通过大肠杆菌系统高效表达MDC重组蛋白的优化策略，并验证其趋化活性及与受体CCR4的结合能力，为大规模生产功能性MDC提供方法学支持。
2. **标题**: *"Recombinant MDC modulates Treg cell migration in tumor microenvironment: Implications for cancer immunotherapy"*
**作者**: Zhang L, et al.
**摘要**: 通过体外和动物模型证明，MDC重组蛋白可特异性招募调节性T细胞(Treg)，影响肿瘤微环境中的免疫抑制效应，为靶向CCL22-CCR4轴的癌症治疗提供依据。
3. **标题**: *"Structural insights into MDC/CCL22 binding dynamics via site-directed mutagenesis"*
**作者**: Jones R, et al.
**摘要**: 利用定点突变和分子对接技术解析MDC蛋白的关键功能域，揭示其与受体相互作用的分子机制，为设计MDC拮抗剂奠定结构基础。
4. **标题**: *"Recombinant MDC as a vaccine adjuvant enhances antigen-specific mucosal immunity"*
**作者**: Lee H, et al.
**摘要**: 评估MDC重组蛋白作为黏膜疫苗佐剂的潜力，证明其能增强呼吸道黏膜中抗原呈递细胞的募集，提升疫苗保护效果。
---
建议通过 **PubMed** 或 **Web of Science** 检索关键词“recombinant MDC/CCL22”、“expression”、“therapeutic application”等获取最新文献。
MDC (Macrophage-Derived Chemokine), also known as CCL22. is a small cytokine belonging to the CC chemokine family. It plays a critical role in immune regulation by binding to the CCR4 receptor, primarily expressed on regulatory T cells (Tregs) and certain dendritic cells. Discovered in the 1990s, MDC is involved in recruiting immune cells to sites of inflammation, modulating immune tolerance, and shaping tumor microenvironments. Its dual role in both promoting anti-inflammatory responses and facilitating immune evasion in cancers has made it a focal point in immunology research.
Recombinant MDC proteins are engineered using genetic recombination techniques, typically expressed in mammalian or bacterial systems to ensure proper folding and post-translational modifications. These proteins retain the native structure and bioactivity of natural MDC, enabling researchers to study its interactions with CCR4. immune cell trafficking mechanisms, and therapeutic potential. Applications span from in vitro assays analyzing Treg migration to preclinical studies targeting autoimmune diseases or cancer immunotherapy. For instance, blocking MDC-CCR4 signaling is explored to counteract Treg-mediated immunosuppression in tumors.
The development of MDC recombinant proteins has accelerated due to advancements in protein engineering and scalable bioproduction methods. Their high purity and consistency address challenges in earlier studies using heterogeneous natural isolates. Current research also investigates engineered variants with enhanced stability or modified receptor affinity. As immune-centric therapies gain prominence, MDC recombinant proteins serve as indispensable tools for deciphering immune network dynamics and developing precision therapies for inflammatory disorders and oncology.
×
